Alpha Cognition (NASDAQ:ACOG) Upgraded by Raymond James to “Moderate Buy” Rating

Alpha Cognition (NASDAQ:ACOG) was upgraded by investment analysts at Raymond James to a “moderate buy” rating in a research report issued on Tuesday,Zacks.com reports.

Separately, HC Wainwright assumed coverage on shares of Alpha Cognition in a research report on Tuesday, March 18th. They set a “buy” rating and a $20.00 price objective for the company.

Alpha Cognition Price Performance

NASDAQ:ACOG opened at $5.52 on Tuesday. Alpha Cognition has a fifty-two week low of $4.66 and a fifty-two week high of $7.00. The firm’s 50 day moving average price is $5.87. The firm has a market cap of $88.43 million, a P/E ratio of -2.16 and a beta of 2.50.

Institutional Investors Weigh In On Alpha Cognition

Large investors have recently added to or reduced their stakes in the business. National Bank of Canada FI acquired a new position in Alpha Cognition in the fourth quarter valued at approximately $69,000. Manatuck Hill Partners LLC acquired a new position in shares of Alpha Cognition during the 4th quarter valued at $395,000. Tudor Investment Corp ET AL bought a new position in shares of Alpha Cognition during the 4th quarter worth about $412,000. MYDA Advisors LLC acquired a new stake in Alpha Cognition in the 4th quarter valued at $589,000. Finally, Bleichroeder LP bought a new stake in Alpha Cognition during the 4th quarter valued at $1,024,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.